Hypertension affects an estimated 1 billion people worldwide, and an estimated 65 million adults in the United States(1,2). It is a major risk factor for heart disease, stroke, congestive heart failure, metabolic syndrome, obstructive sleep apnea and kidney disease. One out of every six adult deaths is attributable to hypertension, and the economic burden in the US exceeds $76.6 Billion. The World Health Organization (WHO) estimates that worldwide, more than 17 million deaths each year are attributable to cardiovascular disease, with hypertension being a substantial contributor to these deaths(3).
A significant subset of the treated patients are medication-resistant or “refractory” and do not achieve target blood pressure levels, despite taking daily doses of three or more medications(4,5,6). In the US, approximately 6 million individuals suffer from refractory hypertension(4).
Renal Denervation has been demonstrated to reduce blood pressure in patients who are not effectively treated by medical therapy. The sympathetic nerves that run along the renal artery play an essential role in controlling blood pressure but, when overactive, contribute to hypertension. De-activating these nerves modulates the signaling process, and helps to reduce blood pressure. Unlike other approaches to renal denervation that depend upon transmural delivery of destructive energy, Ablative Solutions has developed a unique device that delivers treatment directly to the nerves that encircle the renal artery, without damaging the renal artery walls – PeriVascular Renal Denervation (PVRD™).
Ablative Solutions, Inc., was founded in 2011 by Tim Fischell, MD, FACC, and David Fischell, PhD, to address this significant unmet medical need. Ablative Solutions’ technology involves endovascular catheters to provide an efficacious, durable, cost-effective and safe alternative to surgical renal denervation for the treatment of hypertension and other diseases caused by an overactive sympathetic nervous system.
1Hajjar, I., J. M. Kotchen, and T. A. Kotchen. 2006. Hypertension: Trends in Prevalence, Incidence, and Control. Annu. Rev. Public Health. 27:465-490.
2Egan, B. M., Y. Zhao, and R. N. Axon. 2010. US Trends in Prevalence, Awareness, Treatment and Control of Hypertension, 1988-2008. JAMA. 303(20):2043-2050.
3Dib, M. W., R. Riera, and M. B. Ferraz. 2010. Estimated annual cost of arterial hypertension treatment in Brazil. Rev Panam Salud Publica. 27(2):125-131.
4Perselli, S. D. 2011. Prevalence of Resistant Hypertension in the United States, 2003-2008. Hypertension. 57:1076-1080.
5Krum, H., M. Schlaich, R. Whitbourn, P. A. Sobotka, J. Sadowski, K. Bartus, B. Kapelak, A. Walton, H.Sievert, S. Thambar, W. T. Abraham, and M. Esler. 2009. Catheter-based renal sympathietic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet.373:1275-1281.
6Oparil, S. 2011. Can Catheter-Based Renal Denervation Be Used Safely and Effectively to Substantially Reduce Blood Pressure in Treatment-Resistant Hypersensitive Patients. Curr Cardiol Rep.13(6):478-480.